Positron Emission Tomography (PET) with 1-Aminocyclobutane-1-[(11)C]carboxylic Acid (1-[(11)C]-ACBC) for Detecting Recurrent Brain Tumors

K F. Hübner; J A. Thie; G T. Smith; G W. Kabalka; I B. Keller; A B. Kliefoth; S K. Campbell; E Buonocore

doi:10.1016/s1095-0397(98)00010-7

Positron Emission Tomography (PET) with 1-Aminocyclobutane-1-[(11)C]carboxylic Acid (1-[(11)C]-ACBC) for Detecting Recurrent Brain Tumors

Clin Positron Imaging. 1998 Jun;1(3):165-173. doi: 10.1016/s1095-0397(98)00010-7.

Authors

K F. Hübner¹, J A. Thie, G T. Smith, G W. Kabalka, I B. Keller, A B. Kliefoth, S K. Campbell, E Buonocore

Affiliation

¹ Biomedical Imaging Center, Department of Radiology, The University of Tennessee Medical Center at Knoxville (UTMCK), Knoxville, TN, USA

PMID: 14516591
DOI: 10.1016/s1095-0397(98)00010-7

Abstract

This study was done to determine whether 1-[(11)C]ACBC PET has any advantages over 2-[(18)F]FDG PET, CT, or MRI in detecting recurrent brain tumors, and whether quantitative 1-[(11)C]ACBC PET information improves the accuracy of "visual" image interpretation.Twenty patients with recurrent brain tumor underwent dynamic PET. Images were analyzed by visual interpretation; in addition, standardized uptake values (SUVs) and Patlak values (k(1)*k(3)/k) were evaluated.1-[(11)C]ACBC identified 19/20 recurrent brain tumors, [18F]FDG 13/19, MRI 13/19, and CT 8/16. Based on SUVs, the average tumor-to-contralateral gray matter ratio of 1-[(11)C]ACBC was 5.0 and 0.5 for 2-[(18)F]FDG. Mean Patlak values of 1-[(11)C]ACBC were 0.044 +/- 0.047 for high and 0.034 +/- 0.026 for low grade tumors. However, visual interpretation was effective without quantitative PET data.1-[(11)C]ACBC, accurately detects recurrent tumors for selecting biopsy sites and treatment planning.